^
    Back
    Association details:
    Biomarker:KIT V559D
    Cancer:Melanoma
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Int J Cancer
    Title:

    L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

    Excerpt:
    In vitro drug sensitivity for imatinib, dasatinib and nilotinib of Ba/F3 stable transformants expressing KITL576P and KITV559D: (a,b) proliferation inhibition, (c,d) increased apoptosis, and (e,f) decrease in KIT phosphorylation by immunoprecipitation.
    DOI:
    https://doi.org/10.1002/ijc.22681